acalabrutinib + zanubrutinib + pirtobrutinib

**Acalabrutinib + zanubrutinib + pirtobrutinib** is a hypothetical triple combination of Bruton's tyrosine kinase (BTK) inhibitors for potential use in B-cell malignancies such as chronic lymphocytic leukemia (CLL). Acalabrutinib and zanubrutinib are second-generation **covalent BTK inhibitors** with high selectivity, reducing off-target effects compared to first-generation ibrutinib, while pirtobrutinib is a **non-covalent (reversible) BTK inhibitor** effective after covalent BTKi failure. All three target **BTK** to inhibit B-cell receptor signaling, promoting apoptosis in malignant B-cells. No clinical trials or data exist for this specific combination; individual agents are approved or in development for relapsed/refractory CLL/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and other lymphomas by developers AstraZeneca (acalabrutinib, brand Calquence), BeiGene (zanubrutinib, brand Brukinsa), and Eli Lilly (pirtobrutinib, brand Jaypirca).[1][2][3][4][6][7][12]